Adys Mendizabal1, Dylan P Thibault1, James A Crispo1, Adina Paley1, Allison W Willis1. 1. Department of Neurology (AM, DPT, JAC, AP, AWW), University of Pennsylvania Perelman School of Medicine; Department of Neurology Translational Center of Excellence for Neuroepidemiology (DPT, JAC, AWW), Neurological Outcomes and Disparities Research, University of Pennsylvania Perelman School of Medicine; Department of Biostatistics (AWW), Epidemiology and Informatics, University of Pennsylvania; Center for Clinical Epidemiology and Biostatistics (AWW), University of Pennsylvania Perelman School of Medicine; and Leonard Davis Institute of Health Economics (AWW), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Abstract
OBJECTIVE: Readmission is used as a quality indicator and is the primary target outcome for disease-modifying therapy (DMT) for multiple sclerosis (MS). However, data on readmissions for patients with MS are limited. METHODS: Using the US Nationwide Readmissions Database, we performed a retrospective cohort study of adults hospitalized for MS in 2014. Primary study outcomes were within 30- and 90-day readmissions. Descriptive analyses compared patient, clinical, and hospital variables readmission status. Multivariable logistic regression models estimated the associations between these variables and readmission. RESULTS: Of 16,629 individuals meeting the study criteria, most were women (73.7%), aged 35-54 years (48.0%), and Medicare program participants (36.8%). In total, 49.7% of inpatients with MS had 1-2 comorbid medical conditions and 23.7% had 3 or more. Having 3 or more comorbidity conditions associated with increased adjusted odds of the 30-day readmission (adjusted odds ratio [AOR] 1.92, 1.34-2.74). Anemia (AOR 1.62, 1.22-2.14), rheumatoid arthritis/collagen vascular diseases (AOR 2.20, 1.45-3.33), congestive heart failure (AOR 2.43, 1.39-4.24), chronic pulmonary disease (AOR 1.35, 1.02-1.78), diabetes with complications (AOR 2.27, 1.45-3.56), hypertension (AOR 1.25, 1.03-1.53), obesity (AOR 1.35, 1.05-1.73), and renal failure (AOR 1.68, 1.06-2.67) were associated with the 30-day readmission. Medicare insurance and nonroutine discharge were also associated with readmission, whereas patient characteristics (sex, age, and socioeconomic status) were not. The most frequent (26.7%) reason for readmission was multiple sclerosis. Ninety-day analyses produced similar findings. CONCLUSIONS: Comorbid diseases were associated with the readmission for persons with multiple sclerosis. Evaluations of the real-world effectiveness for DMTs in reducing hospitalizations in patients with MS may need to consider comorbid disease burden and management.
OBJECTIVE: Readmission is used as a quality indicator and is the primary target outcome for disease-modifying therapy (DMT) for multiple sclerosis (MS). However, data on readmissions for patients with MS are limited. METHODS: Using the US Nationwide Readmissions Database, we performed a retrospective cohort study of adults hospitalized for MS in 2014. Primary study outcomes were within 30- and 90-day readmissions. Descriptive analyses compared patient, clinical, and hospital variables readmission status. Multivariable logistic regression models estimated the associations between these variables and readmission. RESULTS: Of 16,629 individuals meeting the study criteria, most were women (73.7%), aged 35-54 years (48.0%), and Medicare program participants (36.8%). In total, 49.7% of inpatients with MS had 1-2 comorbid medical conditions and 23.7% had 3 or more. Having 3 or more comorbidity conditions associated with increased adjusted odds of the 30-day readmission (adjusted odds ratio [AOR] 1.92, 1.34-2.74). Anemia (AOR 1.62, 1.22-2.14), rheumatoid arthritis/collagen vascular diseases (AOR 2.20, 1.45-3.33), congestive heart failure (AOR 2.43, 1.39-4.24), chronic pulmonary disease (AOR 1.35, 1.02-1.78), diabetes with complications (AOR 2.27, 1.45-3.56), hypertension (AOR 1.25, 1.03-1.53), obesity (AOR 1.35, 1.05-1.73), and renal failure (AOR 1.68, 1.06-2.67) were associated with the 30-day readmission. Medicare insurance and nonroutine discharge were also associated with readmission, whereas patient characteristics (sex, age, and socioeconomic status) were not. The most frequent (26.7%) reason for readmission was multiple sclerosis. Ninety-day analyses produced similar findings. CONCLUSIONS: Comorbid diseases were associated with the readmission for persons with multiple sclerosis. Evaluations of the real-world effectiveness for DMTs in reducing hospitalizations in patients with MS may need to consider comorbid disease burden and management.
Authors: Jose M Valderas; Barbara Starfield; Bonnie Sibbald; Chris Salisbury; Martin Roland Journal: Ann Fam Med Date: 2009 Jul-Aug Impact factor: 5.166
Authors: P Murali Doraiswamy; Joel Leon; Jeffrey L Cummings; Deborah Marin; Peter J Neumann Journal: J Gerontol A Biol Sci Med Sci Date: 2002-03 Impact factor: 6.053
Authors: Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; James Blanchard; Aruni Tennakoon; Nancy Yu Journal: Neurology Date: 2014-08-01 Impact factor: 9.910
Authors: Cyrus Sh Ho; Liang Feng; Johnson Fam; Rathi Mahendran; Ee Heok Kua; Tze Pin Ng Journal: Int Psychogeriatr Date: 2014-04-15 Impact factor: 3.878
Authors: Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; James Blanchard; Stella Leung; Nancy Yu Journal: Neurology Date: 2015-05-27 Impact factor: 9.910
Authors: Aaron E Miller; Richard Macdonell; Giancarlo Comi; Mark S Freedman; Ludwig Kappos; Mathias Mäurer; Tomas P Olsson; Jerry S Wolinsky; Sylvie Bozzi; Catherine Dive-Pouletty; Paul W O'Connor Journal: J Neurol Date: 2014-06-28 Impact factor: 4.849